title: Bioavailability of Desmin, a low molecular weight dermatan sulfate, after subcutaneous administration to healthy volunteers.
abstract: The bioavailability of two different s.c. doses of Desmin (a new low molecular weight dermatan sulfate) was evaluated in 12 healthy volunteers (6 men, 6 women aged 22-45 years) who were injected, on 3 separate days and with a wash-out period of at least 21 days between each administration, with 200 and 300 mg of Desmin by the s.c. route and 200 mg by the i.v. route. Immediately before injection and at various times thereafter (after 15 min and 30 min for i.v. only and after 1, 2, 3, 4, 6, 8, 12, and 24 h for both s.c. and i.v. dosing), blood samples were drawn to investigate bioavailability by measuring several coagulation parameters: activated partial thromboplastin time, thrombin time, inhibition of factor Xa, Heptest, and heparin cofactor II. Furthermore the local tolerance of the s.c. and i.v. injections were investigated. The s.c. administration of the two Desmin doses had a negligible effect on the activated partial thromboplastin time and a very small effect on the thrombin time, measured with human thrombin; in contrast, Heptest, heparin cofactor II, and anti-Xa activities increased, with a good drug bioavailability (more than 100%). The plasma effects of Desmin were dose dependent only when measured by Heptest, which also gave a greater response after the s.c. administrations. There were no symptoms of intolerance or pain at the injection site after single i.v. and s.c. Desmin administration.
authors.affiliation: Department of Internal Medicine, University of Bologna, Policlinico S. Orsola Malpighi, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Miglioli
authors.forename: L
authors.initials: L
authors.lastname: Pironi
authors.forename: E
authors.initials: E
authors.lastname: Ruggeri
authors.forename: C
authors.initials: C
authors.lastname: Serra
authors.forename: V
authors.initials: V
authors.lastname: Zamboni
authors.forename: M
authors.initials: M
authors.lastname: Barbanti
authors.forename: N
authors.initials: N
authors.lastname: Canova
authors.forename: F
authors.initials: F
authors.lastname: Calanni
authors.forename: M R
authors.initials: MR
authors.lastname: Milani
authors.forename: E
authors.initials: E
authors.lastname: Palazzini
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D001682:Biological Availability; D003871:Dermatan Sulfate / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight
chemical_list: D000925:Anticoagulants; D003871:Dermatan Sulfate